Treatment of cutaneous leishmaniasis by topical 25% podophyllin solution (single, blinded, therapeutic, controlled study)
Background: There are many therapies that had been used to treat cutaneous leishmaniasis (CL). Objective: To evaluate the effectiveness of topical 25% podophyllin solution in treatment of CL. Patients and methods: Sixty-five patients with acute CL enrolled in this study, which was done in the Depart...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2015-07-01
|
Series: | Journal of Dermatology and Dermatologic Surgery |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2352241015000171 |
_version_ | 1818352435206291456 |
---|---|
author | Khalifa E. Sharquie Adil A. Noaimi Ahmed G. Al-Ghazzi |
author_facet | Khalifa E. Sharquie Adil A. Noaimi Ahmed G. Al-Ghazzi |
author_sort | Khalifa E. Sharquie |
collection | DOAJ |
description | Background: There are many therapies that had been used to treat cutaneous leishmaniasis (CL).
Objective: To evaluate the effectiveness of topical 25% podophyllin solution in treatment of CL.
Patients and methods: Sixty-five patients with acute CL enrolled in this study, which was done in the Department of Dermatology, Baghdad Teaching Hospital, Baghdad, during January 2008–April 2009.The total number of lesions was 124 and duration of lesions ranged from 3 to 12(6.84 ± 2.902) weeks. The size of lesions ranged from 0.5 to 3(1.75 ± 1.81) cm. Diagnosis was confirmed by biopsy and smear. Lesions were divided into two groups with matching of type and size of lesions
Group A treated with topical 25% podophyllin solution once weekly for number of sessions ranged from 3 to 6(4.51 ± 0.85) sessions.
Group B was left untreated as a control group. Follow up was every 2 weeks for 8 weeks.
Results: The total number of lesions was 120:79(65.84%) were ulcerated and 41(34.16%) were dry and 25(40.32%) patients had single lesion while 37(59.677%) patients had multiple lesions.
Group A: 51(85%) lesions out of 60 lesions had cure with number of sessions ranging from 3 to 6(5.137 ± 0.9385) sessions.
Group B: no lesion was cured.
Conclusions: Topical 25% podophyllin is a new effective topical therapy for CL, with few side effects. |
first_indexed | 2024-12-13T18:53:35Z |
format | Article |
id | doaj.art-e72d694c7a3e4538b7fbb5683534a8c3 |
institution | Directory Open Access Journal |
issn | 2352-2410 |
language | English |
last_indexed | 2024-12-13T18:53:35Z |
publishDate | 2015-07-01 |
publisher | Wolters Kluwer Medknow Publications |
record_format | Article |
series | Journal of Dermatology and Dermatologic Surgery |
spelling | doaj.art-e72d694c7a3e4538b7fbb5683534a8c32022-12-21T23:34:53ZengWolters Kluwer Medknow PublicationsJournal of Dermatology and Dermatologic Surgery2352-24102015-07-0119210811310.1016/j.jdds.2014.10.001Treatment of cutaneous leishmaniasis by topical 25% podophyllin solution (single, blinded, therapeutic, controlled study)Khalifa E. Sharquie0Adil A. Noaimi1Ahmed G. Al-Ghazzi2Department of Dermatology, College of Medicine, University of Baghdad, Iraqi and Arab Board for Dermatology and Venereology, Baghdad Teaching Hospital, Medical City, Baghdad, IraqDepartment of Dermatology, College of Medicine, University of Baghdad, Iraqi and Arab Board for Dermatology and Venereology, Baghdad Teaching Hospital, Medical City, Baghdad, IraqDepartment of Dermatology and Venereology, Baghdad Teaching Hospital, Medical City, Baghdad, IraqBackground: There are many therapies that had been used to treat cutaneous leishmaniasis (CL). Objective: To evaluate the effectiveness of topical 25% podophyllin solution in treatment of CL. Patients and methods: Sixty-five patients with acute CL enrolled in this study, which was done in the Department of Dermatology, Baghdad Teaching Hospital, Baghdad, during January 2008–April 2009.The total number of lesions was 124 and duration of lesions ranged from 3 to 12(6.84 ± 2.902) weeks. The size of lesions ranged from 0.5 to 3(1.75 ± 1.81) cm. Diagnosis was confirmed by biopsy and smear. Lesions were divided into two groups with matching of type and size of lesions Group A treated with topical 25% podophyllin solution once weekly for number of sessions ranged from 3 to 6(4.51 ± 0.85) sessions. Group B was left untreated as a control group. Follow up was every 2 weeks for 8 weeks. Results: The total number of lesions was 120:79(65.84%) were ulcerated and 41(34.16%) were dry and 25(40.32%) patients had single lesion while 37(59.677%) patients had multiple lesions. Group A: 51(85%) lesions out of 60 lesions had cure with number of sessions ranging from 3 to 6(5.137 ± 0.9385) sessions. Group B: no lesion was cured. Conclusions: Topical 25% podophyllin is a new effective topical therapy for CL, with few side effects.http://www.sciencedirect.com/science/article/pii/S2352241015000171Cutaneous leishmaniasisPodophyllinTreatment |
spellingShingle | Khalifa E. Sharquie Adil A. Noaimi Ahmed G. Al-Ghazzi Treatment of cutaneous leishmaniasis by topical 25% podophyllin solution (single, blinded, therapeutic, controlled study) Journal of Dermatology and Dermatologic Surgery Cutaneous leishmaniasis Podophyllin Treatment |
title | Treatment of cutaneous leishmaniasis by topical 25% podophyllin solution (single, blinded, therapeutic, controlled study) |
title_full | Treatment of cutaneous leishmaniasis by topical 25% podophyllin solution (single, blinded, therapeutic, controlled study) |
title_fullStr | Treatment of cutaneous leishmaniasis by topical 25% podophyllin solution (single, blinded, therapeutic, controlled study) |
title_full_unstemmed | Treatment of cutaneous leishmaniasis by topical 25% podophyllin solution (single, blinded, therapeutic, controlled study) |
title_short | Treatment of cutaneous leishmaniasis by topical 25% podophyllin solution (single, blinded, therapeutic, controlled study) |
title_sort | treatment of cutaneous leishmaniasis by topical 25 podophyllin solution single blinded therapeutic controlled study |
topic | Cutaneous leishmaniasis Podophyllin Treatment |
url | http://www.sciencedirect.com/science/article/pii/S2352241015000171 |
work_keys_str_mv | AT khalifaesharquie treatmentofcutaneousleishmaniasisbytopical25podophyllinsolutionsingleblindedtherapeuticcontrolledstudy AT adilanoaimi treatmentofcutaneousleishmaniasisbytopical25podophyllinsolutionsingleblindedtherapeuticcontrolledstudy AT ahmedgalghazzi treatmentofcutaneousleishmaniasisbytopical25podophyllinsolutionsingleblindedtherapeuticcontrolledstudy |